Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00374933 · ClinicalTrials.gov registry record · Phase 1
Enhancing Graft vs Leukemia Via Delayed Ex-Vivo Co-Stimulated DLI After Non-Myeloablative Stem Cell Transplantation
A Phase 1 study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT00374933 is a Phase 1 study that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 18 participants.
The verdict
NCT00374933, a Phase 1 study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This is a new platform in non-myeloablative allogeneic stem cell transplantation to improve survival by harnessing the immunologic potential of donor T-cells to induce and maintain long-term remissions in patients with hematologic malignancies without undue toxicity. This study involves is the first study in humans directed at optimizing the graft vs leukemia effect by infusing activated T-cells from healthy donors prophylactically, months after recovery from the initial transplant. Investigators are studying whether the activation of donor cells prior to infusion will enhance the patient's ability to "seek and destroy" residual malignant cells while also helping the immune system to fight infection without increasing the immune reaction against the host.
Interventions
- DRUG Non-myeloablative allogeneic stem cell transplant with prophylactic activated DLI
- DRUG "Prophylactic" delayed ADLI
- DRUG "Prophylactic" delayed activated donor lymphocyte infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2007-04 |
| Est. Completion | 2009-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00374933
The ClinicalTrials.gov registry entry for NCT00374933 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Non-myeloablative allogeneic stem cell transplant with prophylactic activated DLI is the first listed.
NCT00374933 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00374933 about?
NCT00374933 is a clinical study titled "Enhancing Graft vs Leukemia Via Delayed Ex-Vivo Co-Stimulated DLI After Non-Myeloablative Stem Cell Transplantation". This is a new platform in non-myeloablative allogeneic stem cell transplantation to improve survival by harnessing the immunologic potential of donor T-cells to induce and maintain long-term remissions in patients with hematologic malignancies without undue toxicity. This study involves is the first...
What is the current status of trial NCT00374933?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2007-04. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00374933?
The interventions under investigation include: Non-myeloablative allogeneic stem cell transplant with prophylactic activated DLI (DRUG), "Prophylactic" delayed ADLI (DRUG), "Prophylactic" delayed activated donor lymphocyte infusion (DRUG).
Who is sponsoring clinical trial NCT00374933?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.